The primary method used to test compounds for anti-cancer activity in cells is flawed, Vanderbilt University researchers reported May 2 in Nature Methods.

Vanderbilt researchers have discovered that activation of a certain signaling pathway protects brain cancers from targeted therapies, suggesting that using therapeutics that block both pathways may be a promising treatment.

Craig Thompson, M.D., president and CEO of Memorial Sloan Kettering Cancer Center, will deliver the next Flexner Discovery Lecture on May 5.

Eric Betzig, Ph.D., who shared the 2014 Nobel Prize in Chemistry for the development of super-resolved fluorescence microscopy, will deliver the next Flexner Discovery Lecture on April 28.

Vanderbilt researchers show that two factors promote the repair of myelin, the nerve cell covering that deteriorates in diseases such as multiple sclerosis.

Vanderbilt researchers show that a certain factor negatively impacts the first-line responder cells in the lungs, providing one explanation for why patients with asthma are at greater risk for invasive bacterial disease.